Cronos Group Inc.
Cronos Group Inc. (CRON.TO) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
cron.to · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Cronos Group Inc. (CRON.TO) measures how much investors pay for each dollar of the company's trailing earnings. CRON.TO's current PE ratio of N/A is calculated by dividing its stock price of $3.85 by its TTM earnings per share of -$0.01.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2013 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 3 fiscal years · Front-end computedMinQ1 · 25%18.7x
MedianQ3 · 75%41.1x
Max
At N/A, CRON.TO's current P/E is lower than in 0% of its annual fiscal year readings over the past 3 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Drug Manufacturers - Specialty & Generic · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Cronos Group Inc.You CRON.TO | $1.4B | N/A | — | -$0.01 |
 Cresco Labs Inc. CL.CN | $439M | N/A | — | -$0.40 |
 Extendicare Inc. EXE.TO | $3.1B | 18.86x | -29.4% | $1.13 |
 Green Thumb Industries Inc. GTII.CN | $2.7B | 16.23x | -39.3% | $0.50 |
 Knight Therapeutics Inc. GUD.TO | $844M | N/A | — | -$0.05 |
 Rubicon Organics Inc. ROMJ.V | $29M | 29.79x | +11.4% | $0.02 |
 Sienna Senior Living Inc. SIA.TO | $2.1B | 42.05x | +57.3% | $0.49 |
Industry Average 4 peers with valid PE | — | 26.73x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-0.03 | — | |
2024-12-31 FY2024 | 18.70x | $0.11 | — | |
2023-12-31 FY2023 | — | $-0.19 | — | |
2022-12-31 FY2022 | — | $-0.46 | — | |
2021-12-31 FY2021 | — | $-1.06 | — | |
2020-12-31 FY2020 | — | $-0.21 | — | |
2019-12-31 FY2019 | 3.08x | $2.49 | — | |
2018-12-31 FY2018 | — | $-0.14 | — | |
2017-12-31 FY2017 | — | $-0.01 | — | |
2016-12-31 FY2016 | — | $-0.01 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Cronos Group Inc. (CRON.TO) measures how much investors pay for each dollar of the company's trailing earnings. CRON.TO's current PE ratio of N/A is calculated by dividing its stock price of $3.85 by its TTM earnings per share of -$0.01.
Frequently asked questions
CRON.TO pe ratio · 6 questionsCRON.TO's current PE ratio is N/A as of 2026-06-08, based on a stock price of $3.85 and TTM EPS of -$0.01. Data sourced from Financial Modeling Prep via CRON.TO's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Cronos Group Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08